Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. November 2017 08:00 ET | Quelle: Lipocine Inc.

U.S. FDA Extends Review for TLANDO™; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged

SALT LAKE CITY, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) has extended the...
08. November 2017 08:00 ET | Quelle: Lipocine Inc.

Lipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017

SALT LAKE CITY, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the three and nine months ended September 30,...
18. Oktober 2017 08:00 ET | Quelle: Lipocine Inc.

FDA Advisory Committee Scheduled to Review TLANDO™ on January 10, 2018

SALT LAKE CITY, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) has scheduled the...
21. September 2017 08:00 ET | Quelle: Lipocine, Inc.

Lipocine Announces Motions Decision by USPTO in Interference Against Clarus

SALT LAKE CITY , Sept. 21, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Patent Trial and Appeal Board (“PTAB”) of the United...
20. September 2017 08:00 ET | Quelle: Lipocine, Inc.

Lipocine Announces FDA Advisory Committee Meeting for TLANDO™

SALT LAKE CITY, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Bone, Reproductive and Urologic Drugs Advisory Committee...
19. September 2017 15:01 ET | Quelle: Lipocine, Inc.

Lipocine to Present at the Ladenburg Thalmann 2017 Healthcare Conference

SALT LAKE CITY, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a...
05. September 2017 08:00 ET | Quelle: Lipocine, Inc.

Lipocine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

SALT LAKE CITY, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a...
14. August 2017 08:00 ET | Quelle: Lipocine, Inc.

Lipocine Announces FDA Acknowledgement of TLANDO™ (“LPCN 1021”) NDA Resubmission; PDUFA Goal Date, February 8, 2018

SALT LAKE CITY, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration (“FDA”) has...
09. August 2017 08:00 ET | Quelle: Lipocine, Inc.

Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism

SALT LAKE CITY, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the resubmission of a New Drug Application (“NDA”) for LPCN 1021,...
07. August 2017 08:00 ET | Quelle: Lipocine, Inc.

Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017

SALT LAKE CITY, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 2017....

Nächste Seite